📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 12:34
0 analysed today
0
Today
136,937
All-time analysed
40,531
Positive
6,324
Negative
82,133
Neutral
7,881
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Q1FY27 Revenue down 42% YoY; Management moderates FY27 growth guidance
Shree Ganesh Remedies reported a weak Q1FY27 with revenue falling 42% YoY to ₹14.36 Cr and PAT declining 68% YoY to ₹1.12 Cr. The downturn was primarily caused by subdued European demand and the termination of a marketing agreement with an EU distributor due to non-performance. Consequently, management has moderated its earlier guidance of 'non-linear growth' for FY27, now expecting a recovery only in the second half of the year. Despite the short-term setback, the company is continuing its Ankleshwar site expansion and Dahej land acquisition for future capacity.
Confidence: HIGH
What changedSignificant quarterly performance decline and a formal moderation of the FY27 growth outlook from 'non-linear' to recovery-based.
Why it mattersThe company is transitioning from a distributor-led model to direct customer engagement in the EU, which creates a short-term volume gap but aims for higher long-term control and margins.
Q1FY27 Revenue: ₹14.36 CrYoY Revenue Change: -42%Q1FY27 PAT: ₹1.12 CrYoY PAT Change: -68%EBITDA Margin: 23.3%Debt to Equity (FY26): 0.18
📅 Short termNegative sentiment is expected due to the sharp earnings miss and the guidance downgrade, with recovery unlikely before H2FY27.
📈 Long termThe structural shift towards niche specialty chemicals and direct EU sales remains the focus, but long-term value depends on the successful execution of the Ankleshwar and Dahej expansions.
⚠ Risk flags
- Geopolitical uncertainty affecting EU demand
- Distributor transition risks
- Volatility in raw material markets
Key Highlights
Revenue from operations fell 42% YoY to ₹14.36 Cr in Q1FY27 compared to ₹24.67 Cr in Q1FY26.
EBITDA margins contracted significantly by 624 bps YoY to 23.3% from 29.6%.
Net Profit (PAT) plummeted 68% YoY to ₹1.12 Cr from ₹3.45 Cr in the previous year's quarter.
Management moderated FY27 guidance from 'non-linear growth' to a 'softer first half' with recovery expected in H2.
Tangible assets increased to ₹68.08 Cr in FY26 from ₹57.91 Cr in FY25, reflecting ongoing capital expenditure.
👀 What to Watch
Monitor the restoration of volumes in the EU market following the distributor termination and the commissioning timeline of 'Block 7' at the Ankleshwar site. Watch for the start of revenue contributions from South-East Asian CRAMS projects in H2FY27 as a recovery signal.
68% PAT drop in Q1FY27; SGRL moderates FY27 growth guidance amid European headwinds
Shree Ganesh Remedies Ltd (SGRL) reported a weak Q1FY27 with revenue declining 42% YoY to ₹14.36 Cr and PAT falling 68% YoY to ₹1.12 Cr. The performance was severely impacted by subdued demand in Europe and the termination of a non-performing distributor agreement, leading management to withdraw its earlier guidance of 'non-linear growth' for FY27. EBITDA margins contracted significantly to 23.3% from 29.6% YoY, reflecting lower operating leverage and raw material volatility. The company expects a recovery in H2FY27 driven by new CRAMS projects and direct customer engagement in Europe.
Confidence: HIGH
What changedSGRL has shifted from a distributor-led model to direct sales in Europe following a contract termination and has officially lowered its growth expectations for FY27.
Why it mattersThe sharp earnings miss and guidance downgrade are significant for a company trading at a high P/E of 44.9, as it indicates a temporary break in the growth trajectory and margin profile.
Q1FY27 Revenue: ₹14.36 CrQ1FY27 PAT: ₹1.12 CrEBITDA Margin: 23.3%YoY Revenue Growth: -42%QoQ PAT Growth: -82%
📅 Short termThe stock is likely to face downward pressure in the short term due to the substantial earnings miss and the withdrawal of aggressive growth guidance.
📈 Long termThe long-term outlook depends on the company's ability to restore volumes through direct sales and the successful execution of its specialty chemicals expansion at the Ankleshwar site.
⚠ Risk flags
- Geopolitical uncertainty affecting European demand
- Execution risk in transitioning to direct sales
- Margin pressure from raw material volatility
- Guidance downgrade
Key Highlights
Revenue for Q1FY27 fell 42% YoY to ₹14.36 Cr, representing only 13.2% of the TTM revenue of ₹109 Cr.
Net Profit (PAT) declined 68% YoY to ₹1.12 Cr, with EPS dropping to ₹0.87 from ₹2.69 in the previous year's quarter.
EBITDA margins compressed by 624 bps YoY and 1,092 bps QoQ to 23.3% due to lower volumes and contract repricing.
Export revenue contributed ₹8.64 Cr (60% of total), but faced headwinds from deferred orders in European markets.
Management moderated FY27 guidance from 'non-linear growth' to a 'softer first half' due to persistent geopolitical uncertainty.
👀 What to Watch
Investors should monitor the timeline for the commissioning of Block 7 and the progress of direct customer acquisition in Europe to replace the terminated distributor. The key recovery trigger will be the commercialization of CRAMS projects in South-East Asia, expected in H2FY27.
Rs 1.15 Cr PAT: Shree Ganesh Remedies reports 67% YoY profit decline in Q1 FY27
Shree Ganesh Remedies (SGRL) reported a weak set of numbers for Q1 FY27, with standalone revenue falling 41.8% YoY to Rs 14.36 Cr. Net profit saw a sharper decline of 66.7% YoY to Rs 1.15 Cr, down from Rs 3.45 Cr in the year-ago period. The results reflect the company's previously stated 'year of consolidation' amid softer demand in Europe and contract repricing in its CRAMS business. The US subsidiary remains non-material with zero revenue for the quarter.
Confidence: HIGH
What changedThe company has transitioned into a significant earnings contraction phase, with Q1 revenue representing only ~13% of the previous TTM revenue, down from a typical ~25% run rate.
Why it mattersThe sharp decline in profitability confirms the impact of external headwinds like European market softness and competitive pricing pressures on the company's high-margin CRAMS model.
Revenue (Q1 FY27): Rs 14.36 CrNet Profit (Q1 FY27): Rs 1.15 CrYoY Revenue Growth: -41.8%YoY PAT Growth: -66.7%Q1 Revenue vs TTM Revenue: 13.2%
📅 Short termThe stock is likely to face downward pressure in the short term as the market reacts to the significant miss in both revenue and profitability.
📈 Long termStructural recovery depends on the commercialization of specialty chemical projects for Japanese clients and the completion of the Ankleshwar expansion by mid-2026.
⚠ Risk flags
- Sharp revenue contraction
- Contract repricing pressure
- Soft demand in European markets
- High inventory volatility
Key Highlights
Revenue from operations declined 41.8% YoY to Rs 14.36 Cr from Rs 24.67 Cr.
Net profit after tax dropped 66.7% YoY to Rs 1.15 Cr from Rs 3.45 Cr.
Earnings Per Share (EPS) fell to Rs 0.89 from Rs 2.69 in Q1 FY26.
Finance costs decreased to Rs 0.32 Cr from Rs 0.94 Cr in the same quarter last year.
Total expenses were reduced to Rs 13.77 Cr, primarily aided by a negative inventory change of Rs 6.31 Cr.
👀 What to Watch
Investors should monitor the stabilization of contract repricing and the execution timeline of the Ankleshwar site expansion, which is critical for growth post-FY26.
67% YoY PAT Drop to ₹1.14 Cr in Q1 FY27 Amid Revenue Contraction
Shree Ganesh Remedies Ltd (SGRL) reported a weak set of results for Q1 FY27, with revenue from operations declining 41.8% YoY to ₹14.36 Cr. Net profit fell sharply by 67% YoY to ₹1.14 Cr, down from ₹3.45 Cr in the same quarter last year. Sequentially, the performance was even more subdued, with revenue dropping 56.7% from ₹33.20 Cr in Q4 FY26. This significant contraction reflects the 'softer demand' and 'contract repricing' challenges previously flagged by the management during their consolidation phase.
Confidence: HIGH
What changedThe company has transitioned from a stable FY26 into a very weak start for FY27, with quarterly revenue hitting its lowest point in over five quarters.
Why it mattersAs a small-cap CRAMS provider, SGRL is highly sensitive to contract timing and pricing; this sharp decline tests the 'consolidation' thesis and highlights the impact of subdued realizations in the chemical sector.
Revenue (Q1 FY27): ₹14.36 CrRevenue Growth (YoY): -41.8%Net Profit (Q1 FY27): ₹1.14 CrQuarterly EPS: ₹0.89Revenue vs TTM Revenue: ~13.2%
📅 Short termThe stock is likely to face downward pressure in the short term due to the significant miss on both top-line and bottom-line expectations.
📈 Long termThe long-term outlook remains tied to the shift toward complex niche specialty chemicals and the successful execution of the Ankleshwar expansion post-FY26.
⚠ Risk flags
- Significant revenue volatility
- Contract repricing pressure
- Soft demand in European markets
- High client concentration risk
Key Highlights
Revenue from operations fell 41.8% YoY to ₹14.36 Cr from ₹24.67 Cr.
Net Profit (PAT) declined 67% YoY to ₹1.14 Cr from ₹3.45 Cr.
Earnings Per Share (EPS) dropped to ₹0.89 from ₹2.69 in Q1 FY26.
Total expenses for the quarter stood at ₹13.77 Cr, representing 90% of total income.
Finance costs decreased significantly to ₹0.32 Cr from ₹0.94 Cr YoY.
👀 What to Watch
Investors should monitor the commercialization timeline of the specialty chemicals project for the Japanese client and the Ankleshwar site expansion, which are the primary long-term growth drivers. Watch for management commentary on whether this sharp revenue dip is a one-off timing issue or a structural slowdown in CRAMS demand.
Rs 14.36 Cr Revenue: Shree Ganesh Remedies Reports 41.8% YoY Revenue Decline in Q1 FY27
Shree Ganesh Remedies reported a weak set of numbers for Q1 FY27, with revenue from operations falling 41.8% YoY to Rs 14.36 crore. Net profit plummeted 67.2% YoY to Rs 1.13 crore, down from Rs 3.45 crore in the same period last year. Sequentially, the performance was even more subdued, with revenue dropping 56.7% from Rs 33.20 crore in Q4 FY26. This sharp contraction aligns with management's earlier guidance of FY26 being a 'year of consolidation' amid softer European demand and contract repricing.
Confidence: HIGH
What changedThe company has reported a significant year-on-year and sequential contraction in both its top-line and bottom-line for the first quarter of FY27.
Why it mattersThe results confirm the immediate impact of softer demand in Europe and downward contract repricing, which are currently outweighing the company's technical expertise in complex chemistry.
Revenue (Q1 FY27): Rs 14.36 crNet Profit (Q1 FY27): Rs 1.13 crYoY Revenue Growth: -41.8%QoQ Revenue Growth: -56.7%EPS (Q1 FY27): Rs 0.88
📅 Short termThe stock is likely to face negative sentiment in the short term due to the sharp decline in quarterly profitability and revenue.
📈 Long termLong-term recovery depends on the successful shift toward niche specialty chemicals and the commercialization of new capacity at the Ankleshwar site.
⚠ Risk flags
- Significant revenue contraction
- Sharp decline in net profit margins
- Exposure to softer demand in European markets
Key Highlights
Revenue from operations fell 41.8% YoY to Rs 14.36 crore from Rs 24.67 crore.
Net profit declined 67.2% YoY to Rs 1.13 crore compared to Rs 3.45 crore.
Quarterly EPS dropped to Rs 0.88 from Rs 2.69 in the year-ago quarter.
Finance costs decreased to Rs 0.32 crore from Rs 0.94 crore in Q1 FY26.
Total expenses for the quarter were reduced to Rs 13.77 crore, down from Rs 20.73 crore YoY.
👀 What to Watch
Investors should monitor the stabilization of CRAMS contract pricing and the progress of the Ankleshwar site expansion, which is key to post-FY26 growth. Watch for updates on the specialty chemicals project for the Japanese client expected by mid-2026.
